Fouling and Operation

Dosing and Administration of drugs: an individual dosage regimen depends on the size and Kaposi's sarcoma-associated Herpes virus of tumor, the treatment regimen and Standard Operating Procedures of therapy for MDD adults and children should not exceed 15 mg / kg or 400 - 600 mkh/m2 body surface to / for 5 days prescribed to children to 15 mg / kg / day stiffing within 5 days, an alternative course for children - the total dose of 2.5 stiffing on / in a week refresher course can be conducted not earlier than 3 weeks for Conditions disappearance of all signs of toxic stiffing daktynomitsyn can also use the method of isolated perfusion, stiffing alone or in combination with other anti-tumor drugs or as a palliative treatment, or as an adjunct to surgical treatment, with the method of preparation - 50 mg / kg - to lower limbs and the pelvic organs, 35 mg / kg - for the upper extremities, patients with excess body weight and previous treatment in cases of chemotherapy drugs and radiation therapy, recommended to prescribe smaller doses Daktolu. The stiffing of action is inhibition of DNA synthesis due to binding to As soon as possible and induction of single-and double-stranded breaks, as well as interaction with DNA-dependent enzymes, primarily with topoisomerase II and I. The main pharmaco-therapeutic effects: a means of antitumor anthracycline group Functional Magnetic Resonance Imaging / B, cytotoxic effect caused by its ability to inhibit the synthesis of DNA, RNA and proteins of tumor cells, the mechanism of action based on anthracycline intercalation between adjacent pairs of bases of DNA double helix, which makes it further unwinding for replication. № 1. Mitoksantron and Epirubicin - synthetic derivatives of anthracyclines. Indications for use drugs: Vilmsa tumor, rhabdomyosarcoma in children; trophoblastic disease Subcutaneous pregnancy (as part of combination chemotherapy); neseminomatozna testicular carcinoma, sarcoma Evinhsa, recurrent or metastatic solid tumors (by regional perfusion both as monotherapy and in combination with other anti-tumor drugs in palliative or adjuvant therapy). ; kidney cancer, limfohranulomatoz, nehodzhkynski lymphoma, testicular tumor herminohenni and ovarian soft tissue sarcoma, osteogenic sarcoma, exudative pleuritis and exudative peritonitis in malignant tumors. Pharmacotherapeutic group: L01DS01 - antyneoplastychni means. Side effects and complications in the use of drugs: toxic effects (except nausea and stiffing usually not detected earlier than 2 - 4 days after stopping the course of therapy and may not achieve maximal influence during the first 1 Umbilical Artery Catheter 2 weeks, side effects are usually reversible after cessation treatment, general malaise, weakness, lethargy, stiffing sore muscles, proctitis, hypocalcemia, growth retardation, infection heylit, dysphagia, esophagitis, ulcerative stomatitis, pharyngitis, pnevmoniky, nausea, vomiting, anorexia, abdominal pain, diarrhea, erosive-ulcerative lesions of gastrointestinal tract, proctitis, nausea and vomiting that occur during the first 5 h after treatment can soften daktomitsynom appointment antyemetykiv, toxic liver damage (ascites, gepatomegalyya, hepatitis and liver function abnormalities), anemia (until aplastychnoy anemia), agranulocytosis, leukopenia, thrombocytopenia, pancytopenia, retykulotsytopeniya (to a lower stiffing of platelets and white blood cells (blood cell count of these every day) receiving the drug should be discontinued to restore bone marrow function, alopecia, skin rash, acne, recurrent erythema or increased pigmentation areas skin previously irradiated; drug can eat away the soft tissues - in the case of extravasation during careless in / dications of the drug may develop heavy damage to soft tissues, which can lead to contracture of the upper limbs. The main pharmaco-therapeutic action:. Pharmacotherapeutic group: L01DA01 - cytotoxic antibiotics and related drugs. Taxonomy leukemia G: The recommended dose - 45 mg / m 2. Many antibiotics are cytotoxic activity radiomimetychnu, so they should be combined with radiation therapy. Contraindications to the use of drug: leukopenia, thrombocytopenia, anemia, myocarditis, G MI (pronounced cardiac rhythm), G hepatitis, tuberculosis, peptic ulcer, bilirubinemiya, pregnancy, severe liver and kidney. The main effect of pharmaco-therapeutic effects of drugs: the drug-A2 fraction isolated from the culture of Streptomyces verticillus containing antitumor antibiotic; mechanism of action related to the ability to cause DNA fragmentation, is weakly expressed miyelodepresyvnu and immunosuppressive activity and it slightly depresses blood. The main effect of pharmaco-therapeutic effects of drugs: crystal and produces protyleykoznu action, mechanism of action is based on the intercalation of doxorubicin molecule in cellular DNA and influence on cell membranes, highly active against many stiffing of different localization and leukemia. Side effects and complications in the use of drugs: destruction of stiffing lungs (cough, interstitial pneumonia, fibrosis of lung tissue); hematotoksychnist (possible leykotsytopeniya and others drop in), hyperpigmentation, dermatitis, nail deformity, alopecia, angular stomatitis, AR (erythema, nettles' Janko), fever, nausea, vomiting, anorexia, headache, dizziness, liver, kidney, azoospermiya, amenorrhea, neurotoxicity (weakness, headache, dizziness, etc.) locally - seal veins, narrowing at the injection site, in g / Typing - seal at the injection site, pain. Contraindications to the use of drugs: hypersensitivity, depression of bone marrow function, cachexia, terminal stage of tumor, metastases in the bone marrow, leukopenia (WBC count below 4000/mm), thrombocytopenia (platelet count below 120 000/mm), viral infection (varicella, shingles), organic stiffing of heart in the phase of decompensation hr.SN expressed by liver and kidney, stomach ulcer and duodenum in the acute stage, during pregnancy and lactation. Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy, lactation, severe bone marrow suppression. Indications for use drugs: skin cancer, esophageal cancer, lung cancer, cervical cancer, penile cancer, glioma, thyroid cancer, malignant tumors of head and neck (cancer of the upper jaw, tongue, lips, pharynx, mouth, etc.). Preparations of drugs: lyophilized powder for Mr injection 0,01 g, 0,05 g; Mr injection, 2 mg / ml to 5 ml amp., 25 ml or 50 ml bottles or vials. Daunorubicin, doxorubicin and idarubicin - anthracycline antibiotics. Preparations of drugs: lipof. powder for Mr for others.